Randomized Controlled Trial of Argatroban With Tissue Plasminogen Activator (tPA) for Acute Stroke "ARTSS-2"


Phase 2 Results N/A

Summary of Purpose

Randomized controlled clinical trial to estimate overall treatment benefit (improvement in disability) among stroke patients treated with rt-PA who are randomized to also receive either low-dose Argatroban, high-dose Argatroban or neither. Trial Stopped: Begin a new study to test the safety of combining IA with tPA and Argatroban.

Read More →

Trial Milestones

The following dates are available for this trial. Trial information last updated on 11 May 2015.

1 Oct 2011 1 Nov 2011 1 Dec 2015 1 Dec 2015 1 May 2015 Unavailable
Start Date First Received 1st Completion Completion Verification Results

Trial Design

  • Allocation: Randomized
  • Masking: Double Blind (Subject, Outcomes Assessor)
  • Purpose: Treatment
  • Endpoint: Safety/Efficacy Study
  • Intervention: Parallel Assignment